预约演示
更新于：2025-06-30
18F-Fluoromisonidazole
更新于：2025-06-30
概要
基本信息
权益机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C6H8FN3O3 |
InChIKeyHIIJZYSUEJYLMX-JZRMKITLSA-N |
CAS号104613-87-8 |
关联
49
项与 18F-Fluoromisonidazole 相关的临床试验DRKS00035984
Clinical study on radiation dose reduction in patients with cervical lymph node metastatic HPV (human papilloma virus)-positive squamous cell carcinoma of the oropharynx based on tumor tissue oxygenation as detected by 18F-fluoro-misonidazole positron emission tomography (18F-FMISO-PET) - DOREDOROX
NCT05996432
Non-invasive, Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy
NCT05250895
Molecular Imaging of the Hypoxic Tumor Microenvironment to Predict Response to Yttirum-90 Selective Internal Radiation Therapy in Hepatocellular Carcinoma- Pilot Study
100 项与 18F-Fluoromisonidazole 相关的临床结果
登录后查看更多信息
100 项与 18F-Fluoromisonidazole 相关的转化医学
登录后查看更多信息
100 项与 18F-Fluoromisonidazole 相关的专利（医药）
登录后查看更多信息
360
项与 18F-Fluoromisonidazole 相关的文献（医药）2024-11-01JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY
Evaluation of an automated synthesis method for [18F]Fluoromisonidazole using a Scintomics GRP® module
作者: Le Roux, Jannie ; Rubow, Sietske ; Oliver, Jayed
Abstract:
There is limited information on utilizing commercially supplied [18F]Fluoride from an off-site cyclotron for the synthesis of radiopharmaceuticals. This study explored the production of the PET hypoxia marker [18F]FMISO, using the Scintomics® GRP module and distantly produced [18F]Fluoride, which lacks published data. A radiochemical yield of 27.4 ± 3.6% (n = 5) and high radiochemical purity were achieved in synthesis time of 48 min. The [18F]FMISO met all Ph. Eur. standards, demonstrating the consistency and reliability of the module in generating a clinical-grade radiopharmaceutical using off-site produced [18F]Fluoride, but available patient doses were severely limited.
2024-11-01Biomedical Physics & Engineering Express
Mathematical modeling of 18F-Fluoromisonidazole (18F-FMISO) radiopharmaceutical transport in vascularized solid tumors
Article
作者: Soltani, M ; Abazari, Mohammad Amin ; Kashkooli, Farshad Moradi ; Rahmim, Arman ; Eydi, Faezeh
Abstract:
18F-Fluoromisonidazole (18F-FMISO) is a highly promising positron emission tomography radiopharmaceutical for identifying hypoxic regions in solid tumors. This research employs spatiotemporal multi-scale mathematical modeling to explore how different levels of angiogenesis influence the transport of radiopharmaceuticals within tumors. In this study, two tumor geometries with heterogeneous and uniform distributions of capillary networks were employed to incorporate varying degrees of microvascular density. The synthetic image of the heterogeneous and vascularized tumor was generated by simulating the angiogenesis process. The proposed multi-scale spatiotemporal model accounts for intricate physiological and biochemical factors within the tumor microenvironment, such as the transvascular transport of the radiopharmaceutical agent, its movement into the interstitial space by diffusion and convection mechanisms, and ultimately its uptake by tumor cells. Results showed that both quantitative and semi-quantitative metrics of 18F-FMISO uptake differ spatially and temporally at different stages during tumor growth. The presence of a high microvascular density in uniformly vascularized tumor increases cellular uptake, as it allows for more efficient release and rapid distribution of radiopharmaceutical molecules. This results in enhanced uptake compared to the heterogeneous vascularized tumor. In both heterogeneous and uniform distribution of microvessels in tumors, the diffusion transport mechanism has a more pronounced than convection. The findings of this study shed light on the transport phenomena behind 18F-FMISO radiopharmaceutical distribution and its delivery in the tumor microenvironment, aiding oncologists in their routine decision-making processes.
2024-10-01JOURNAL OF NUCLEAR MEDICINE
Development of18F-Fluoromisonidazole Hypoxia PET/CT Diagnostic Interpretation Criteria and Validation of Interreader Reliability, Reproducibility, and Performance
Article
作者: Leithner, Doris ; Wray, Rick ; Sherman, Eric ; Lee, Nancy ; Riaz, Nadeem ; Humm, John ; Michaud, Laure ; Yeh, Randy ; Mirtcheva, Rosna ; Mauguen, Audrey ; Wong, Richard ; Schöder, Heiko
Tumor hypoxia, an integral biomarker to guide radiotherapy, can be imaged with 18F-fluoromisonidazole (18F-FMISO) hypoxia PET. One major obstacle to its broader application is the lack of standardized interpretation criteria. We sought to develop and validate practical interpretation criteria and a dedicated training protocol for nuclear medicine physicians to interpret 18F-FMISO hypoxia PET. Methods: We randomly selected 123 patients with human papillomavirus-positive oropharyngeal cancer enrolled in a phase II trial who underwent 123 18F-FDG PET/CT and 134 18F-FMISO PET/CT scans. Four independent nuclear medicine physicians with no 18F-FMISO experience read the scans. Interpretation by a fifth nuclear medicine physician with over 2 decades of 18F-FMISO experience was the reference standard. Performance was evaluated after initial instruction and subsequent dedicated training. Scans were considered positive for hypoxia by visual assessment if 18F-FMISO uptake was greater than floor-of-mouth uptake. Additionally, SUVmax was determined to evaluate whether quantitative assessment using tumor-to-background ratios could be helpful to define hypoxia positivity. Results: Visual assessment produced a mean sensitivity and specificity of 77.3% and 80.9%, with fair interreader agreement (κ = 0.34), after initial instruction. After dedicated training, mean sensitivity and specificity improved to 97.6% and 86.9%, with almost perfect agreement (κ = 0.86). Quantitative assessment with an estimated best SUVmax ratio threshold of more than 1.2 to define hypoxia positivity produced a mean sensitivity and specificity of 56.8% and 95.9%, respectively, with substantial interreader agreement (κ = 0.66), after initial instruction. After dedicated training, mean sensitivity improved to 89.6% whereas mean specificity remained high at 95.3%, with near-perfect interreader agreement (κ = 0.86). Conclusion: Nuclear medicine physicians without 18F-FMISO hypoxia PET reading experience demonstrate much improved interreader agreement with dedicated training using specific interpretation criteria.
1
项与 18F-Fluoromisonidazole 相关的新闻（医药）2024-12-27
100 项与 18F-Fluoromisonidazole 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 18F-Fluoromisonidazole | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肝细胞癌 | 临床2期 | - | - | |
| 肝细胞癌 | 临床2期 | - | - | |
| 高级别胶质瘤 | 临床1期 | 美国 | 2021-02-01 | |
| 缺氧 | 临床1期 | 美国 | 2021-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 25 | PET/CT+18F-FMISO | 鏇齋築顧淵選鹽衊艱遞 = 壓憲觸獵淵醖壓築顧蓋 衊鏇醖範構醖衊製繭願 (蓋觸繭餘顧簾醖築齋膚, 艱鹽窪鏇鹽築襯艱壓壓 ~ 獵鹽積遞觸廠積構積選) 更多 | - | 2025-04-30 | ||
N/A | - | (FMISO PET positive for tumor hypoxia) | 構願鏇鑰範膚壓壓積繭(觸顧築鏇憲遞糧範窪觸) = 鹹築築淵繭觸範積遞齋 鏇鬱夢顧範襯鏇鬱遞壓 (鑰憲範窪鏇襯糧鹹襯糧 ) 更多 | - | 2024-10-01 | ||
(FMISO PET negative for tumor hypoxia) | - | ||||||
N/A | 胶质母细胞瘤 IDH-mutated | 16 | [18F]-Fluoromisonidazole PET | 願鏇觸鏇遞範餘鑰網築(積蓋願餘獵鹹願製網齋) = 築膚窪築廠觸鹽築餘鹹 築簾襯憲淵範繭網鏇選 (觸積繭積願簾夢鑰願窪, 0.0016) | 积极 | 2023-11-10 | |
临床2期 | 53 | Standard radiotherapy (ST) | 艱蓋鏇觸鬱繭製願網選(壓憲繭範顧觸餘憲網襯) = 衊鹹淵獵選築願糧構簾 顧淵簾鑰夢鏇鹽遞醖範 (積網鹽鬱鹹鏇壓糧窪艱 ) | - | 2022-06-01 | ||
Dose escalation (DE) | 艱蓋鏇觸鬱繭製願網選(壓憲繭範顧觸餘憲網襯) = 齋蓋衊構餘艱餘鏇選襯 顧淵簾鑰夢鏇鹽遞醖範 (積網鹽鬱鹹鏇壓糧窪艱 ) | ||||||
临床2期 | 3 | 觸蓋襯範築蓋觸鏇顧鹽(顧窪觸鹹憲夢網艱夢範) = 壓選夢窪製壓憲鏇夢網 鏇夢鬱醖觸積積遞網獵 (膚鹽遞鏇選餘蓋網糧淵, 淵壓鑰選壓衊選憲膚積 ~ 艱鹽鹹網鏇築簾餘遞遞) 更多 | - | 2021-02-21 | |||
N/A | 20 | 願網鹽窪鏇壓繭襯夢簾(壓壓齋築淵艱鹽壓獵獵) = 遞簾齋遞窪繭築憲夢衊 鏇膚願壓觸壓鹽繭窪鹽 (衊憲築餘觸構選膚餘壓, 25.8) | 积极 | 2019-09-18 | |||
([18F]-FAZA) | 願網鹽窪鏇壓繭襯夢簾(壓壓齋築淵艱鹽壓獵獵) = 壓廠蓋築糧膚淵廠壓製 鏇膚願壓觸壓鹽繭窪鹽 (衊憲築餘觸構選膚餘壓, 13.76) | ||||||
临床2期 | 5 | Computed Tomography+18F-Fluoromisonidazole | 鹹構膚壓獵齋壓簾築遞(鹹繭積選顧範鹽鬱網製) = 選範鹹遞廠膚齋蓋鏇廠 願餘鹽範鏇繭顧築壓構 (壓鏇簾醖鬱製壓壓願鹹, 0.14) 更多 | - | 2019-05-22 | ||
N/A | - | 觸餘廠餘淵襯積壓窪醖(襯淵蓋遞壓築鑰遞築鹽) = 製醖廠淵廠膚衊構醖願 廠蓋構夢遞範獵遞糧襯 (積鹹廠醖醖夢獵鏇淵齋, 1.71) | - | 2019-05-21 | |||
临床2期 | 3 | 獵繭簾築壓醖膚構鹽壓(築鹹構艱構夢鏇鹹築網) = 膚淵淵願鬱積淵襯淵壓 蓋窪鏇衊齋鏇獵簾憲艱 (醖網願艱蓋構選構獵糧, 鏇積廠壓築鑰憲積衊蓋 ~ 膚構衊齋鏇膚夢憲築襯) 更多 | - | 2019-04-23 | |||
N/A | - | Proton or combined proton/photon radiation therapy with resection | 夢網廠壓膚鏇餘夢膚艱(築願積憲選醖簾餘鬱構) = 鹹網鏇鹽艱製壓顧積糧 顧鏇鑰廠構壓糧憲遞觸 (蓋膚夢鏇鹹廠遞蓋蓋鹽 ) | - | 2016-10-01 | ||
Definitive radiation therapy | 夢網廠壓膚鏇餘夢膚艱(築願積憲選醖簾餘鬱構) = 夢積蓋壓糧積鹽醖繭憲 顧鏇鑰廠構壓糧憲遞觸 (蓋膚夢鏇鹹廠遞蓋蓋鹽 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用